Hemab Therapeutics Holdings
COAG
39.29
-0.57
-1.43%
Hemab Therapeutics Holdings
US · COAG
#3007 by market cap
Listed 2026
39.29
-0.57
-1.43%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
Wedbush Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Maintains Target Price $42Market Newswire · 2026/6/30
-
Rating change
H.C. Wainwright Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $60Market Newswire · 2026/8/12
-
Rating change
Wedbush Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $64Market Newswire · 2026/8/12
-
Rating change
Hemab Therapeutics Holdings, Inc. (COAG) Receives a Buy From WedbushTipRanks · 2026/6/30
-
Rating change
Jefferies Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Maintains Target Price $39Market Newswire · 2026/6/9
-
Rating change
Wedbush Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $42Market Newswire · 2026/5/26
-
Rating change
Hemab Therapeutics Holdings, Inc. (COAG) Gets a Buy From WedbushTipRanks · 2026/8/12
-
Rating change
Evercore Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $50Market Newswire · 2026/5/26
-
Wedbush Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Maintains Target Price $64Market Newswire · 2026/11/6
-
Rating change
H.C. Wainwright Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Maintains Target Price $40Market Newswire · 2026/6/27
-
J.P. Morgan Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $70Market Newswire · 2026/10/16
-
Rating change
H.C. Wainwright Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $40Market Newswire · 2026/6/17
-
Rating change
Analysts Offer Insights on NA Companies: Cleanspark (CLSK), Hemab Therapeutics Holdings, Inc. (COAG) and Microsoft (MSFT)TipRanks · 2026/10/16
-
Earnings Flash (COAG) Hemab Therapeutics Posts Q3 Net Loss $0.58 a Share, Vs. FactSet Est of $0.49 LossMT Newswires · 2026/11/10
-
Rating change
Rodman & Renshaw Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $56Market Newswire · 2026/10/12
-
Evercore Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $65Market Newswire · 2026/11/11
-
Rating change
Jefferies Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $47Market Newswire · 2026/7/14
-
LifeSci Capital Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $65Market Newswire · 2026/11/9
-
Rating change
Wedbush Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $55Market Newswire · 2026/7/14
-
Rating change
H.C. Wainwright Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $52Market Newswire · 2026/7/13
-
Rating change
Goldman Sachs Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $36Market Newswire · 2026/5/26
-
Rating change
Jefferies Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $39Market Newswire · 2026/5/26
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Hemab Therapeutics Holdings discussion 0 comments